AI assistant
ABBOTT LABORATORIES — Director's Dealing 2021
Feb 24, 2021
29777_dirs_2021-02-23_29f36716-f3fd-4f29-b177-71e1a0bfdad3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2021-02-19
Reporting Person: Scoggins Christopher J (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-19 | Common shares without par value | A | 12484 | — | Acquired | 52190 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-02-19 | Option (right to buy) | $124.04 | A | 63991 | Acquired | 2031-02-18 | Common Shares (63991) | Direct |
Footnotes
F1: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
F2: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 21,330 on February 19, 2022, 21,330 on February 19, 2023, and 21,331 on February 19, 2024.